MSFT   212.19 (-0.99%)
FB   241.25 (-1.33%)
GOOGL   1,505.56 (-0.86%)
AMZN   3,178.53 (-0.13%)
CGC   16.15 (+0.81%)
BABA   257.02 (-1.74%)
TSLA   1,388.51 (-0.41%)
AMD   57.05 (-0.37%)
T   29.75 (+0.71%)
ACB   11.89 (+1.02%)
GILD   76.15 (+1.93%)
DIS   117.72 (+0.77%)
BA   174.17 (+0.51%)
MSFT   212.19 (-0.99%)
FB   241.25 (-1.33%)
GOOGL   1,505.56 (-0.86%)
AMZN   3,178.53 (-0.13%)
CGC   16.15 (+0.81%)
BABA   257.02 (-1.74%)
TSLA   1,388.51 (-0.41%)
AMD   57.05 (-0.37%)
T   29.75 (+0.71%)
ACB   11.89 (+1.02%)
GILD   76.15 (+1.93%)
DIS   117.72 (+0.77%)
BA   174.17 (+0.51%)
MSFT   212.19 (-0.99%)
FB   241.25 (-1.33%)
GOOGL   1,505.56 (-0.86%)
AMZN   3,178.53 (-0.13%)
CGC   16.15 (+0.81%)
BABA   257.02 (-1.74%)
TSLA   1,388.51 (-0.41%)
AMD   57.05 (-0.37%)
T   29.75 (+0.71%)
ACB   11.89 (+1.02%)
GILD   76.15 (+1.93%)
DIS   117.72 (+0.77%)
BA   174.17 (+0.51%)
MSFT   212.19 (-0.99%)
FB   241.25 (-1.33%)
GOOGL   1,505.56 (-0.86%)
AMZN   3,178.53 (-0.13%)
CGC   16.15 (+0.81%)
BABA   257.02 (-1.74%)
TSLA   1,388.51 (-0.41%)
AMD   57.05 (-0.37%)
T   29.75 (+0.71%)
ACB   11.89 (+1.02%)
GILD   76.15 (+1.93%)
DIS   117.72 (+0.77%)
BA   174.17 (+0.51%)
Log in

OTCMKTS:INNVInnovus Pharmaceuticals Stock Price, Forecast & News

$1.23
0.00 (0.00 %)
(As of 02/14/2020)
Add
Compare
Today's Range
$1.11
Now: $1.23
$1.23
50-Day Range
$1.23
MA: $1.23
$1.23
52-Week Range
$0.75
Now: $1.23
$11.50
Volume13,279 shs
Average Volume21,102 shs
Market Capitalization$3.94 million
P/E RatioN/A
Dividend YieldN/A
Beta2.1
Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, ketones, krill oil, omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; UriVarx, a supplement for overactive bladder and urinary incontinence; PEVarx, a supplement for peak sexual performance; ProstaGorx, a supplement for prostate support; and FlutiCare, a nasal spray. In addition, its products include Apeaz for pain relief; AllerVarx for allergy relief; ArthriVarx for joint pain; Xyralid, a hemorrhoid cream; Can-C eye drop and eye care capsule; MZS, a melatonin formula to enhance sleep patterns; and Diabasens, a diabetic foot cream. The company's pipeline products comprise UriVarx for urinary tract infection; Xyralid suppositories for hemorrhoidal symptoms; GlucoGorx supplement, glucometer, lancing device, and GlucoGorx strip for blood sugar levels; Vesele and RecalMax nitric oxide strips. It markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.
Read More
Innovus Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.16 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:INNV
Previous SymbolNASDAQ:INNV
CUSIPN/A
Phone858-964-5123

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.99 million
Book Value$0.05 per share

Profitability

Net Income$-8,280,000.00

Miscellaneous

Employees27
Market Cap$3.94 million
Next Earnings DateN/A
OptionableNot Optionable

Receive INNV News and Ratings via Email

Sign-up to receive the latest news and ratings for INNV and its competitors with MarketBeat's FREE daily newsletter.

Innovus Pharmaceuticals (OTCMKTS:INNV) Frequently Asked Questions

How has Innovus Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Innovus Pharmaceuticals' stock was trading at $1.23 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, INNV shares have increased by 0.0% and is now trading at $1.23. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Innovus Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innovus Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Innovus Pharmaceuticals.

How were Innovus Pharmaceuticals' earnings last quarter?

Innovus Pharmaceuticals Inc (OTCMKTS:INNV) posted its quarterly earnings results on Tuesday, August, 14th. The company reported ($0.01) earnings per share for the quarter. The company earned $7.31 million during the quarter. Innovus Pharmaceuticals had a negative return on equity of 1,611.96% and a negative net margin of 35.85%. View Innovus Pharmaceuticals' earnings history.

What price target have analysts set for INNV?

1 brokers have issued 1 year price objectives for Innovus Pharmaceuticals' stock. Their forecasts range from $5.00 to $5.00. On average, they expect Innovus Pharmaceuticals' share price to reach $5.00 in the next twelve months. This suggests a possible upside of 306.5% from the stock's current price. View analysts' price targets for Innovus Pharmaceuticals.

Has Innovus Pharmaceuticals been receiving favorable news coverage?

Media headlines about INNV stock have been trending somewhat positive on Friday, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Innovus Pharmaceuticals earned a news impact score of 1.8 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about Innovus Pharmaceuticals.

Who are some of Innovus Pharmaceuticals' key competitors?

What other stocks do shareholders of Innovus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innovus Pharmaceuticals investors own include EEStor (ESU), Antares Pharma (ATRS), Federal National Mortgage Association (FNMA), The Medicines (MDCO), Frontier Communications (FTR), FedEx (FDX), Republic First Bancorp (FRBK), NVIDIA (NVDA), Aytu Bioscience (AYTU) and Pacific Premier Bancorp (PPBI).

Who are Innovus Pharmaceuticals' key executives?

Innovus Pharmaceuticals' management team includes the following people:
  • Dr. Bassam B. Damaj, Pres, CEO & Director (Age 51)
  • Mr. Ryan J. Selhorn CPA, VP & CFO (Age 37)
  • Mr. Randy J. Berholtz, Exec. VP of Corp. Devel., Gen. Counsel & Sec. (Age 58)
  • Mr. Christopher Stella, VP of Operations
  • Mr. Robert C. Verfurth, VP of Sales & Marketing

What is Innovus Pharmaceuticals' stock symbol?

Innovus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "INNV."

How do I buy shares of Innovus Pharmaceuticals?

Shares of INNV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Innovus Pharmaceuticals' stock price today?

One share of INNV stock can currently be purchased for approximately $1.23.

How big of a company is Innovus Pharmaceuticals?

Innovus Pharmaceuticals has a market capitalization of $3.94 million and generates $23.99 million in revenue each year. The company earns $-8,280,000.00 in net income (profit) each year or ($4.16) on an earnings per share basis. Innovus Pharmaceuticals employs 27 workers across the globe.

What is Innovus Pharmaceuticals' official website?

The official website for Innovus Pharmaceuticals is www.innovuspharma.com.

How can I contact Innovus Pharmaceuticals?

Innovus Pharmaceuticals' mailing address is 8845 Rehco Road, San Diego CA, 92121. The company can be reached via phone at 858-964-5123 or via email at [email protected]

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.